XMT 1522

Drug Profile

XMT 1522

Alternative Names: XMT-1522

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Adimab; Mersana Therapeutics
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunotoxins
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer
  • Preclinical Gastric cancer

Most Recent Events

  • 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union
  • 05 Dec 2016 Phase-I clinical trials in Breast cancer (Second-line therapy or greater, Inoperable/Unresectable, Metastatic disease) in USA (IV) (NCT02952729)
  • 24 Oct 2016 US FDA approves IND application for XMT 1522 in HER2 expressing cancers
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top